We are happy to welcome Peter Olofsson-Sahl to the Iscaff team! Peter has extensive experience both as researcher and entrepreneur, and from management of large development projects. From May [...]
Iscaffpharma have announced that the company’s first US patent, with patent no US 11,840,732 B2 has been issued by the United States Patent and Trademark Office (USPTO) on December 12th, 2023. [...]
We are proud to welcome Thais Fenz Araujo to Iscaffpharma. Thais holds a pHD in medical science and has a strong background in human & synthetic 3D cancer models. She will be responsible for [...]
Iscaffpharma and Elena Garre has been invited to present at SLAS Europe in Brussels. We are humbled that our technology gains such interest from the the research community and are confident that [...]
Iscaffpharma announces Sara Malcus as new chair of the board from May 2023. Sara brings experience from several start-ups and successful companies within biotech. We are proud to welcome Sara to [...]
Iscaffpharma and Professor Göran Landberg invited to give a key note presentation on the importance of the tumor microenvironment at SLAS meeting building biology in 3D in Cambridge 20-21 st of [...]
Gothenburg University, RISE and Iscaffpharma received the prestigious grant support and are partnering with AstraZeneca (LSE/STO/Nasdaq: AZN), for a project to develop synthetic 3D-models that [...]
Published patent application for the use of patient derived scaffolds within immune-oncology The patent application covers the use of cell-free scaffolds as a predictive tool in assessing cancer [...]
